Cargando…

New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors

The pro-apoptotic tumor suppressor BIN1 inhibits the activities of the neoplastic transcription factor MYC, poly (ADP-ribose) polymerase-1 (PARP1), and ATM Ser/Thr kinase (ATM) by separate mechanisms. Although BIN1 deficits increase cancer-cell resistance to DNA-damaging chemotherapeutics, such as c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Folk, Watson P., Kumari, Alpana, Iwasaki, Tetsushi, Cassimere, Erica K., Pyndiah, Slovénie, Martin, Elizabeth, Homlar, Kelly, Sakamuro, Daitoku
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704450/ https://www.ncbi.nlm.nih.gov/pubmed/34948122 http://dx.doi.org/10.3390/ijms222413324

Ejemplares similares

Restoration of tumor suppressor functions by small-molecule inhibitors
por: Pyndiah, Slovénie, et al.
Publicado: (2015)

The Dual Roles of MYC in Genomic Instability and Cancer Chemoresistance
por: Kumari, Alpana, et al.
Publicado: (2017)

Mechanisms of Cisplatin-Induced Apoptosis and of Cisplatin Sensitivity: Potential of BIN1 to Act as a Potent Predictor of Cisplatin Sensitivity in Gastric Cancer Treatment
por: Tanida, Satoshi, et al.
Publicado: (2012)

Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition
por: Aguilar-Quesada, Rocío, et al.
Publicado: (2007)

Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia
por: Oei, Arlene L., et al.
Publicado: (2017)

p27(Kip1) Is Required to Mediate a G1 Cell Cycle Arrest Downstream of ATM following Genotoxic Stress
por: Cassimere, Erica K., et al.
Publicado: (2016)

Viral Particle-Mediated SAMHD1 Depletion Sensitizes Refractory Glioblastoma to DNA-Damaging Therapeutics by Impairing Homologous Recombination
por: Daddacha, Waaqo, et al.
Publicado: (2022)

PI3Kδ activates E2F1 synthesis in response to mRNA translation stress
por: Gnanasundram, Sivakumar Vadivel, et al.
Publicado: (2017)

ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition
por: Gilardini Montani, Maria Saveria, et al.
Publicado: (2013)

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib()
por: Wang, Chen, et al.
Publicado: (2017)

Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition
por: D’Ambrosio, Concetta, et al.
Publicado: (2022)

RYBP Sensitizes Cancer Cells to PARP Inhibitors by Regulating ATM Activity
por: Maybee, Deanna V., et al.
Publicado: (2022)

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
por: Stewart, C. Allison, et al.
Publicado: (2017)

Layer‐by‐layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum‐based drug resistance therapy in ovarian cancer
por: Mensah, Lawrence B., et al.
Publicado: (2019)

Loss of ATM kinase activity leads to embryonic lethality in mice
por: Daniel, Jeremy A., et al.
Publicado: (2012)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer
por: Albany, Costantine, et al.
Publicado: (2020)

Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study
por: Sayal, Karen, et al.
Publicado: (2015)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

Synthetic Lethality of Cohesins with PARPs and Replication Fork Mediators
por: McLellan, Jessica L., et al.
Publicado: (2012)

Inhibition of ATM kinase rescues planarian regeneration after lethal radiation
por: Shiroor, Divya A, et al.
Publicado: (2023)

Paralog-based synthetic lethality: rationales and applications
por: Xin, Yucui, et al.
Publicado: (2023)

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
por: Mendes-Pereira, Ana M, et al.
Publicado: (2009)

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
por: Srinivasan, Gayathri, et al.
Publicado: (2017)

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
por: Ha, Kyungsoo, et al.
Publicado: (2014)

The PARP3- and ATM-dependent phosphorylation of APLF facilitates DNA double-strand break repair
por: Fenton, Amanda L., et al.
Publicado: (2013)

ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors
por: Parvin, Sultana, et al.
Publicado: (2023)

ATM and MET kinases are synthetic lethal with non-genotoxic activation of p53
por: Sullivan, Kelly D., et al.
Publicado: (2012)

Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer
por: Grochot, Rafael, et al.
Publicado: (2023)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy
por: Yusoh, Nur Aininie, et al.
Publicado: (2020)

The Number of Platinum Atoms Binding to DNA, RNA and Protein Molecules of HeLa Cells Treated with Cisplatin at Its Mean Lethal Concentration
por: Akaboshi, Mitsuhiko, et al.
Publicado: (1992)

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development
por: Virtanen, Verneri, et al.
Publicado: (2019)

Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine
por: Murata, Stephen, et al.
Publicado: (2016)

Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors
por: Angers, Stephane
Publicado: (2021)

Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality
por: Le, Bac Viet, et al.
Publicado: (2022)

The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
por: Li, Shuangying, et al.
Publicado: (2022)

Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
por: Williamson, Chris T, et al.
Publicado: (2012)

53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
por: Hong, Ruoxi, et al.
Publicado: (2016)

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
por: Lloyd, Rebecca L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2u0omkjc9pt2f13b9sec2opgu2